Intellia Therapeutics Named Edward Dulac Of Fate Therapeutics As CFO, Effective July 22, Succeeding Glenn Goddard
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics (NASDAQ:NTLA) has appointed Edward Dulac as the new CFO, effective July 22, 2024, succeeding Glenn Goddard. Dulac brings over 20 years of experience in finance, business development, and corporate strategy, having previously served as CFO of Fate Therapeutics.
June 26, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics has appointed Edward Dulac as the new CFO, effective July 22, 2024. Dulac's extensive experience in finance and biotech could positively impact the company's strategic direction and investor confidence.
The appointment of a highly experienced CFO like Edward Dulac is likely to be viewed positively by investors, as it suggests strong leadership and strategic direction for Intellia Therapeutics. Dulac's background in finance and biotech, including his previous role at Fate Therapeutics, adds credibility and could enhance investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100